Patent ID: 8530469
Filing Date: 2013-09-10
Classification: A61P,C07C,C07D

Abstract:
1. A combination comprising: (i) an Hsp90 inhibitor compound of the formula (VII): or tautomer thereof; wherein n is 1, 2 or 3; R 1 and R 2a are both hydroxy; R 3 is selected from isopropyl and tert-butyl; R 4a is hydrogen; R 8 is hydrogen; R 10b is selected from a group consisting of halogen, OH, NH 2 , CH 2 OH, CH 2 NH 2 , O—C 1-6 -alkyl, NH—C 1-6 alkyl, aryl, heteroaryl, C 3-7 cycloalkyl, heterocyclyl, O-heteroaryl, O—C 3-7 cycloalkyl, O-heterocycloalkyl, C(═O)C 1-6 alkyl, C(═O)OC 1-6 alkyl, C(═O)NH 2 , C(═O)NHC 1-6 alkyl, C(═O)N(C 1-6 alkyl) 2 , NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 , NC(═O)C 1-6 alkyl, C 6 aryl, OC 6 aryl, C(═O)C 6 aryl, C(═O)OC 6 aryl, C(═O)NH 2 , C(═O)NHC 6 aryl, C(═O)N(C 6 aryl) 2 , NH(C 6 aryl), N(C 6 aryl) 2 , NC(═O)C 6 aryl, C 5-6 heterocyclyl, OC 5-6 heterocyclyl, C(═O)C 5-6 heterocyclyl, C(═O)OC 5-6 heterocyclyl, C(═O)NHC 5-6 heterocyclyl, C(═O)N(C 5-6 heterocyclyl) 2 , NH(C 5-6 heterocyclyl), N(C 5-6 heterocyclyl) 2 , NC(═O)C 5-6 heterocyclyl, C(═O)NHC 1-6 alkyl, C 5-6 aryl, S(═O)C 1-6 alkyl, S(═O)N—C 1-6 alkyl and SO 2 N—C 1-6 alkyl; and a group [sol], CH 2 [sol] or OCH 2 CH 2 [sol] where [sol] is selected from the following groups (ii) one or more therapeutic agents selected from topoisomerase I inhibitors; antimetabolites; tubulin targeting agents; DNA binder and topoisomerase II inhibitors; alkylating agents; monoclonal antibodies; anti-hormones; signal transduction inhibitors; proteasome inhibitors; DNA methyl transferases; cytokines; retinoids and HDAC or HAT modulators.